Selecting the TP method

Example 13 — Pharma R&D — milestone pricing

Draft (June 2026) · Annex I · Example 13 · ¶51–55 · Pharma Co

OECD discussion draft, June 2026 (not final)
At a glance
Company A engages a specialised affiliate (Company B) to run clinical trials using its own proprietary computational biology. The risk of R&D failure is borne by Company A, but Company B contributes unique IP and proven outcome-shortening capability. How is Company B compensated?
Company A
R&D principal · owns and exploits drug IP · bears R&D failure risk
data analysis & trials
Company B
Clinical trials with proprietary analytics IP
  1. Pharma Co centralises drug development in Company A (subsidiary that owns and exploits drug IP).
  2. Company A engages Company B for data analysis and patient stratification using Company B's own IP and track record.
  3. At contract date, the probability that any new drug succeeds is highly uncertain.
  4. Compensation is structured to keep Company B operating on a rolling basis and to incentivise specific clinical milestones.

Company A owns the drug IP and bears the risk of R&D failure. Company B brings its own analytics IP, designs and runs the trials, takes the related risks — and has a track record of speeding up timelines.

What pricing structure fits Company B?

OECD analysis · Milestone-based remuneration
Based on industry practices documented by Company A, the remuneration is structured to ensure Company B can continue its operations on a rolling basis while incentivising successful clinical milestones, taking into account the risks Company B assumes and the IP it uses in providing the services.
Key takeaway
Where a service provider contributes unique IP and bears meaningful risks, pure cost-plus is rarely arm's length. Structures that combine baseline coverage with success-linked rewards can better reflect the parties' contributions.

Related: Chapter VI (intangibles) · Example 15 (contract research vs. unique R&D)

Test yourself on this example.Open it in the interactive walkthrough →